Fig. 2From: Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspectiveOne way sensitivity analysis tornado diagram. QALY: quality-adjusted life year; PF: progression-free; PD: progressed disease; BSC: best supportive care; PemCis: pemetrexed-cisplatinBack to article page